In Europe, the debate on health has shifted from the need to foster innovation to concerns over the long-term sustainability of healthcare systems. In most cases, the price of medicines is being strongly scrutinised.
For companies, it is no longer enough to simply present a strong clinical data package to secure a marketing authorisation and then expect policymakers and pricing and reimbursement authorities to accept a high price. A new approach is needed to ensure the optimal uptake of innovative treatments. And the market access landscape across Europe is varied, complex, and changing fast.
Our Navigating Market Access in Europe report helps to outline the system to help companies navigate the complexities.
Read more below:
We will be at the BIO Convention in Philadelphia from June 3-6 so please let us know if you’ll be there too and would like to learn more about the changing European healthcare landscape.